A focused tracking guide for Semax used solo, with an emphasis on separating real cognitive signal from caffeine and sleep effects.
At a glance
Best for
Semax is a synthetic heptapeptide derived from a fragment of ACTH (4-10), modified for stability. It was developed in Russia and is used there clinically for stroke recovery and cognitive indications. This post covers Semax used by itself — a dedicated tracking framework, separate from the existing combined Selank/Semax post in Peptide IA.
Semax appears to increase BDNF and NGF expression in animal models, modulate dopaminergic and serotonergic tone, and produce neuroprotective effects in ischemia models. The subjective report from most users is increased focus, mental stamina under fatigue, and sometimes a mild mood lift. It is not a classical stimulant — there is no peripheral activation, no heart rate change, no come-down crash for most people.
Intranasal is the standard route — oral bioavailability is negligible. Concentrations vary widely (regular Semax, NA-Semax, Selank-Semax blends) and matter more than vial volume. Protocols are typically short cycles, often a few weeks on with breaks. Some users dose only on demanding workdays rather than continuously.
Semax effects are usually noticeable but not dramatic. People expecting modafinil-level wakefulness will be disappointed. The effect is more of a "stable focus under cognitive load" sensation. Most controlled human data comes from Russian stroke recovery trials, not healthy cognitive enhancement, so the nootropic use case is largely off-label and self-reported. Tolerance and adaptation over weeks of continuous use are commonly described.
In Peptide IA, a daily focus slider, dose log with concentration noted, caffeine in milligrams, and sleep hours. Weekly: a chart of focus on dose days versus non-dose days, holding sleep and caffeine roughly constant. After a cycle, take two weeks off and compare baseline focus to your on-cycle average. That gap is your real effect estimate.
Semax has decades of Russian clinical use behind it with a fairly clean profile, but long-term Western data and large RCTs are limited. Not approved by the FDA or EMA. Intranasal mucosal irritation is the most common complaint. People on antidepressants or stimulant medications should be cautious about stacking, as the dopaminergic and serotonergic effects are not well characterized in combination.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.